Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05097885

Health Benefits of Whole-body Vibration

The overall goals of this pilot investigation are to determine 1) the feasibility of conducting home based WBV studies, and 2) to determine if sub-acute home based WBV can improve a) exercise capacity, b) conduit- and micro- vascular function, and c) skeletal muscle function.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Whole-body Vibration

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology

Augusta, Georgia, 30912, United States

Location status: Recruiting

Location contact

Casey Derella, BS

CONTACT

[email protected]

706-721-5483

Ryan Harris, PhD, CEP

CONTACT

[email protected]

706-721-5998

About this study

Cardiovascular disease (CVD) is the leading cause of death in the world and many comorbid conditions (i.e. diabetes, obesity) can affect overall CVD risk. There is increasing interest into the role that skeletal muscle health plays in mediating CVD risk, particularly in metabolic disease states (ie. obesity and diabetes). Whole body vibration (WBV) has emerged as an exercise mimetic that may be more tolerable than traditional modes of exercise, such as treadmill walking/running or cycling. Similar to traditional exercise modalities, WBV can elicit beneficial metabolic effects. In fact, a single bout of WBV increases circulating concentrations of IL-6, which correspond with the normalization of glucose and insulin in obese individuals. The proposed pilot investigation will provide the foundation to begin understanding the molecular and physiological mechanisms of how sub-acute WBV can improve overall CVD risk. We hypothesize that home based WBV will decrease CVD risk by improving skeletal muscle and vascular function via a decrease in systemic inflammation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women (> 18 yrs old)
  • All races

Exclusion criteria

  • <18 years old
  • Clinical diagnosis of hepatic, cardiovascular, or renal disease
  • Diabetic complications (i.e. macrovascular, microvascular, or autonomic)
  • Pregnancy
  • Direct vasoactive medications (i.e. nitrates)

Treatment and study plan

Sub Acute Whole Body Vibration Training

Other

Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.

Primary outcomes

  1. Change in VO2 Peak

    Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    change from baseline relative (mL/kg/min) peak oxygen consumption (VO2) during maximal exercise test at 12 weeks

  2. Change in Flow-Mediated Dilation (FMD)

    Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    change from baseline brachial artery flow mediated dilation at 12 weeks.

  3. Change in Skeletal Muscle Mitochondrial Function

    Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    change from baseline skeletal muscle mitochondrial function at 12 weeks. Measured using Near Infrared Spectroscopy (NIRS). Values are an index of phosphocreatine recovery expressed as a rate constant (min-1)

  4. Change in Pulse Wave Velocity (PWV)

    Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    Change from baseline PWV at 12 weeks. Measured by Shygmocor Xcel in m/s.

  5. Change in Post Occlusive Reactive Hyperemia (PORH)

    Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    Change from baseline PORH at 12 weeks. Measured by Laser Speckle Contrast Imager (Moor FLPI).

  6. Change in IL-6

    Time frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    change from baseline concentrations of Interleukin 6 (IL-6) obtained via blood draw at 12 weeks.

Study contacts

Contact information is provided by the study sponsor or research team.

Jacob Looney, MS

CONTACT

[email protected]

7067215483

Ryan Harris, PhD

CONTACT

[email protected]

7067215998

Sponsors and collaborators

Lead sponsor

Augusta University

Other

Registry information

Official study title

Pilot Investigation on the Health Benefits of Sub Acute (12 Week) Whole-body Vibration Training

Acronym: VIBE-Rx

Important dates

Study start
2022
Primary completion
2027
Study completion
2028
First posted
Oct 28, 2021
Registry last updated
Jan 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.